Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus
Yuji Kondo, Jason L. Larabee, Liang Gao, Huiping Shi, Bojing Shao, Christopher M. Hoover, J. Michael McDaniel, Yen-Chun Ho, Robert Silasi-Mansat, Stephanie A. Archer-Hartmann, Parastoo Azadi, R. Sathish Srinivasan, Alireza R. Rezaie, Alain Borczuk, Jeffrey C. Laurence, Florea Lupu, Jasimuddin Ahamed, Rodger P. McEver, James F. Papin, Zhongxin Yu, Lijun Xia
Yuji Kondo, Jason L. Larabee, Liang Gao, Huiping Shi, Bojing Shao, Christopher M. Hoover, J. Michael McDaniel, Yen-Chun Ho, Robert Silasi-Mansat, Stephanie A. Archer-Hartmann, Parastoo Azadi, R. Sathish Srinivasan, Alireza R. Rezaie, Alain Borczuk, Jeffrey C. Laurence, Florea Lupu, Jasimuddin Ahamed, Rodger P. McEver, James F. Papin, Zhongxin Yu, Lijun Xia
View: Text | PDF
Research Article Cell biology Vascular biology

L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus

  • Text
  • PDF
Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a pandemic. Severe disease is associated with dysfunction of multiple organs, but some infected cells do not express ACE2, the canonical entry receptor for SARS-CoV-2. Here, we report that the C-type lectin receptor L-SIGN interacted in a Ca2+-dependent manner with high-mannose–type N-glycans on the SARS-CoV-2 spike protein. We found that L-SIGN was highly expressed on human liver sinusoidal endothelial cells (LSECs) and lymph node lymphatic endothelial cells but not on blood endothelial cells. Using high-resolution confocal microscopy imaging, we detected SARS-CoV-2 viral proteins within the LSECs from liver autopsy samples from patients with COVID-19. We found that both pseudo-typed virus enveloped with SARS-CoV-2 spike protein and authentic SARS-CoV-2 virus infected L-SIGN–expressing cells relative to control cells. Moreover, blocking L-SIGN function reduced CoV-2–type infection. These results indicate that L-SIGN is a receptor for SARS-CoV-2 infection. LSECs are major sources of the clotting factors vWF and factor VIII (FVIII). LSECs from liver autopsy samples from patients with COVID-19 expressed substantially higher levels of vWF and FVIII than LSECs from uninfected liver samples. Our data demonstrate that L-SIGN is an endothelial cell receptor for SARS-CoV-2 that may contribute to COVID-19–associated coagulopathy.

Authors

Yuji Kondo, Jason L. Larabee, Liang Gao, Huiping Shi, Bojing Shao, Christopher M. Hoover, J. Michael McDaniel, Yen-Chun Ho, Robert Silasi-Mansat, Stephanie A. Archer-Hartmann, Parastoo Azadi, R. Sathish Srinivasan, Alireza R. Rezaie, Alain Borczuk, Jeffrey C. Laurence, Florea Lupu, Jasimuddin Ahamed, Rodger P. McEver, James F. Papin, Zhongxin Yu, Lijun Xia

×

Figure 5

L-SIGN is a receptor for SARS-CoV-2 virus.

Options: View larger image (or click on image) Download as PowerPoint
L-SIGN is a receptor for SARS-CoV-2 virus.
(A) Representative confocal m...
(A) Representative confocal microscopy images of SARS-CoV-2 nucleocapsid protein in LSECs from a COVID-19 liver autopsy sample. An uninfected normal human liver autopsy sample was used as a negative control. LSECs were L-SIGN+ (green). Arrows mark SARS-CoV-2 (red). DAPI (gray), nuclear staining. Scale bar: 10 μm. (B) Representative of 3D rendering of Z-stacked microscopy of liver sections from COVID-19 liver autopsy samples. Scale bars: 3 μm. Arrows mark SARS-CoV-2 protein particles (red) inside LSECs. Scale bar: 5 μm. (C) Representative 3D reconstructed confocal microscopy images of sections from a COVID-19 liver autopsy sample (left). Images on the right show orthogonal xy, xz, and yz projections of the dotted area to reveal the virus staining inside the LSEC. Scale bars: 10 μm. The results represent data from biopsy of autopsy samples of 4 independent patients with COVID-19 and 3 uninfected patients. (D) Representative confocal microscopy images of cultured L-SIGN-flag–expressing LSECs infected with authentic SARS-CoV-2 (MOI = 1). Scale bar: 5 μm. Blue (DAPI), nuclear staining; green, L-SIGN; red, nucleocapsid protein. (E) A 3D microscopy view of L-SIGN-flag–expressing LSECs infected with authentic SARS-CoV-2 (MOI = 1). Scale bar: 5 μm. Green, L-SIGN; red, nucleocapsid protein. (F) Percentage of nucleocapsid protein+ cells per total cells in 4–8 ×40 fields in mock- or L-SIGN-flag–transduced LSECs. (G) Median tissue culture infectious dose (TCID50) virus titer assay of supernatants 2 days after infection in mock-, L-SIGN-flag–, or ACE2-myc3–transduced LSECs. Infected Vero-E6 cells were positive control in terms of their permissiveness for high viral productivity. (H) Percentage of nucleocapsid protein+ cells per total L-SIGN-flag–transduced LSECs in the presence of mannan (100 and 500 μg/ml) in 4–8 ×40 fields in each group. *P < 0.01; **P < 0.0001. Bars indicate the mean; error bars represent mean ± SD. All experiments were at least repeated 3 times.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts